IL2RA and breast cancer: This correlation with BC-CML patients allowed us also to discover the expression in PB32-ENU of a group of genes also expressed in patients in BC-CML (Figure 6G) and among which some are potential targets such as IL2RA (CD25). CD25 has already been described in AML blasts, BC-CML, and LSCs [46,47] as an aberrant marker and related to bad prognosis; it is also a potential target for new therapies in BC-CML and AML.